noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Healthcare

Pappas Capital LLC

11/13/2023 | Press release | Archived content

Tune Therapeutics Reveals Epigenetic Editing Program Targeting He...

News | 11. 13. 2023

Tune Therapeutics

DURHAM, N.C. & SEATTLE-- November 13, 2023--Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection. The program was unveiled by Dr. Ed Gane, Professor of Medicine at the University of Auckland and world-renowned authority on Hepatitis B Virus (HBV) at the American Association for the Study of Liver Diseases (AASLD) conference in Boston, MA on November 11^th. The program, described by Gane at a session on emerging HBV treatments, aims to utilize TEMPO -Tune's proprietary 'genetic tuning' platform - to achieve functional cure through the permanent, epigenetic repression of viral activity.

Pappas Capital LLC published this content on November 13, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 09:57 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format